Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$173.33 USD

173.33
7,686,410

+1.80 (1.05%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $173.73 +0.40 (0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks News

Swarup Gupta headshot

Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs

The index enjoyed quite a positive week even as a yield curve inversion weighed on broader markets.

Zacks Equity Research

Axsome's Depression Drug Gets Breakthrough Therapy Status

Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).

Zacks Equity Research

AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

Zacks Equity Research

This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Swarup Gupta headshot

5 Cancer-Fighting Stocks to Boost Portfolio Gains

It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.

Zacks Equity Research

J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group

J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population

Zacks Equity Research

3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock

Johnson & Johnson (JNJ) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million

Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.

Zacks Equity Research

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $136.61, marking a -0.22% move from the previous day.

Zacks Equity Research

J&J Files Application for Darzalex Label Expansion in Europe

J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

Zacks Equity Research

Cooper Companies' (COO) CooperVision Gains Momentum Globally

Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

Zacks Equity Research

Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

Zacks Equity Research

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

Zacks Equity Research

Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

Zacks Equity Research

Company News For Mar 15, 2019

Companies In The News Are: BA, DG, JNJ, WAGE

Zacks Equity Research

J&J Seeks Approval for Darzalex in Expanded Patient Group

J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.

Zacks Equity Research

Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $138.56, marking a +0.36% move from the previous day.

Zacks Equity Research

Bayer Submits Application in EU for Prostate Cancer Drug

Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Zacks Equity Research

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

Neena Mishra headshot

Can Smart Beta & Factor ETFs Beat the Market?

Here is what investors need to know about smart beta and factor strategies that combine the best aspects of active and passive investing.

Zacks Equity Research

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.